含替诺福韦或齐多夫定的高效抗逆转录病毒治疗方案的疗效比较和耐药分析

发布时间：2018-03-04 00:15

本文选题：获得性免疫缺陷综合征　切入点：高效抗逆转录病毒治疗　出处：《实用医学杂志》2015年09期 　论文类型：期刊论文

【摘要】：目的:比较含替诺福韦(TDF)或含齐多夫定(AZT)的2种高效抗逆转录病毒治疗(HAART)方案的疗效和耐药情况。方法:回顾收集2010年10月至2013年11月接受2种不同组合HAART方案治疗的艾滋病患者共235例,其中AZT组133例,TDF组102例,比较2组治疗12个月后CD4+T淋巴细胞计数上升的平均值及上升幅度、病毒学失败及耐药情况。结果:2组基线CD4+T淋巴细胞计数、男女比例、年龄、感染方式等具有可比性;2组治疗12个月CD4+T淋巴细胞计数的平均值以及CD4+T淋巴细胞计数的上升幅度比较差异无显著性(P0.05);病毒学失败3例均发生在AZT组,但2组比较差异无统计学意义(P0.05);AZT组有1例发生核苷类似物相关突变(TAMs)并对AZT高度耐药。结论 :2种HAART方案对艾滋病治疗的免疫学效果相当,在病毒学方面,含AZT组出现2.2%的失败率,但尚未能证明与AZT有直接关系。
[Abstract]:Objective: to compare the efficacy and drug resistance of two highly effective antiretrovirals (HAART) regimen containing tenofovir (TDF) or azidovudine (AZT). Methods: from October 2010 to November 2013, two different combinations of HAART regimens were collected. 235 AIDS patients were treated. There were 133 cases in AZT group, 102 cases in TDF group. The average value and increase range of CD4 T lymphocyte count, virological failure and drug resistance were compared after 12 months of treatment in two groups. Results the baseline CD4 T lymphocyte count, ratio of male to female, age in two groups were compared. There was no significant difference in the average value of CD4 T lymphocyte count and the increase of CD4 T lymphocyte count in the two groups after 12 months of treatment, but there was no significant difference between the two groups (P 0.05), and the three cases of virology failure occurred in the AZT group. However, there was no significant difference between the two groups in one patient in the P0.05AZT group who developed a nucleoside analogue related mutation (TAMs) and was highly resistant to AZT. Conclusion the immunological effects of the two HAART regimens on AIDS are comparable, and in virology, there is no significant difference between the two groups. There was a failure rate of 2.2% in the AZT group, but there was no direct correlation with AZT.
【作者单位】：广州中医药大学热带医学研究所;广西中医药大学附属瑞康医院;
【基金】：2014国家科技重大专项(编号:2014ZX10005002) 国家自然科学基金面上项目(编号:81360258)
【分类号】：R512.91

【参考文献】